FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503) 10903 New Hampshire Avenue, Silver Spring, Maryland October 10, 2018

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren Tesh, PharmD, BCPS

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Massimo Cristofanilli, MD, FACP

Associate Director of Translational Research and Precision Medicine Robert H. Lurie Comprehensive Cancer Center Chicago, Illinois

Christian S. Hinrichs, MD

Investigator & Lasker Clinical Research Scholar **Experimental Transplantation and Immunology** National Cancer Institute (NCI) National Institutes of Health (NIH) Bethesda, Maryland

Grzegorz S. Nowakowski, MD

Associate Professor of Medicine and Oncology Mayo Clinic Rochester Rochester, Minnesota

Thomas S. Uldrick, MD, MS

Deputy Head, Global Oncology Associate Member, Vaccine and Infectious Disease Division Associate Member, Clinical Research Division Fred Hutchinson Cancer Research Center Seattle, Washington

Susan Halabi, PhD

Professor of Biostatistics and Bioinformatics **Duke University Medical Center** Durham, North Carolina

Heidi D. Klepin, MD, MS

Associate Professor of Internal Medicine Section of Hematology and Oncology Wake Forest University Health Sciences Winston Salem, North Carolina

Brian I. Rini, MD, FACP

(Chairperson) Professor of Medicine, Lerner College of Medicine Leader, GU Program Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting October 10, 2018

DRAFT MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP

(Industry Representative)
Executive Medical Director, Amgen Oncology
Therapeutic Area Head, US Medical Organization
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

Andy Chen, MD, PhD

Associate Professor of Medicine Division of Hematology and Medical Oncology Oregon Health and Science University Portland, Oregon

William S. Hancock, PhD

Bradstreet Chair in Bioanalytical Chemistry, Barnett Institute and Department of Chemistry and Chemical Biology Northeastern University Boston, Massachusetts

Adel H. Karara, PhD, FCP

Professor of Pharmaceutical Sciences University of Maryland Eastern Shore Princess Anne, Maryland

Tracy G. Mason

(Patient Representative)
Little Rock, Arkansas

Scott A. Waldman, MD, PhD

Chair, Department of Pharmacology and Experimental Therapeutics Samuel MV Hamilton Professor Thomas Jefferson University Director, GI Malignancies Program Kimmel Cancer Center Philadelphia, Pennsylvania

Jerry M. Collins, PhD

Associate Director for Developmental Therapeutics Division of Cancer Treatment and Diagnosis NCI, NIH Bethesda, Maryland

Randy Hawkins, MD

(Acting Consumer Representative)
Private Practice
Inglewood, California

Eric O. Long, PhD

Head, Molecular and Cellular Immunology Laboratory of Immunogenetics National Institute of Allergy and Infectious Diseases, NIH Rockville, Maryland

Paul J. Smith, PhD

Associate Professor of Statistics Director, Mathematical Statistics Program University of Maryland College Park, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting October 10, 2018

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Ann Farrell, MD

Director

Division of Hematology Products (DHP) Office of Hematology and Oncology Products (OHOP)

Office of New Drugs (OND), CDER, FDA

Nicole Gormley, MD

Deputy Director (Acting) DHP, OHOP, OND, CDER, FDA

Vishal Bhatnagar, MD

Medical Officer Team Leader (Acting) DHP, OHOP, OND, CDER, FDA

Sue Lim, MD

Director of the Scientific Review Staff Therapeutic Biologics and Biosimilars Staff (TBBS) OND, CDER, FDA

Steven Kozlowski, MD

Director

Office of Biotechnology Products (OBP) Office of Pharmaceutical Quality (OPQ) CDER, FDA

Christopher Downey, PhD

Review Chief

Division of Biotechnology Review and Research IV OBP, OPQ, CDER, FDA